Connect with us

Business

Austrianova Singapore, A Partner Of Pharmacyte Biotech Inc (OTCMKTS:PMCB), Completes Final Production Run: Austrianova Ships Final Product For Release Testing

Published

on

Austrianova Singapore, a partner Of Pharmacyte Biotech Inc (OTCMKTS:PMCB), has completed the second and final run of the GMP manufacturing process that will be used for the production of Pharmacyte’s clinical trial product. The clinical trial product of Pharmacyte is ready for release testing. The information collected from release testing in both the manufacturing runs would be included in the IND (an investigational new drug application). It will be sent to the US FDA for supporting the planned clinical trial of Pharmacyte in patients suffering from inoperable and advanced pancreatic cancer.

Austrianova ships frozen syringes for lab testing

Austrianova has filled the genetically modified live cells into clinical trial syringes of Pharmacyte and frozen. It has shipped a frozen syringe sample to Europe for release testing in a third-party lab. The lab will test the safety of the final release product. Austrianova will then conduct the functionality test of the live encapsulated cells in its in-house.

Kenneth L. Waggoner, CEO of PharmaCyte, said the company is excited to complete the two production runs. It is now ready to progress towards submitting IND to the US FDA to begin the clinical trial in inoperable and advanced pancreatic cancer.

Changes the future of curing diseases

The technology of Pharmacyte expects to make a change in the way several hard to cure diseases are treated soon. The company would offer a new lease of life to LAPC (locally advanced, inoperable pancreatic cancer) patients by reducing the size of the tumors by inching closer in its upcoming phase 2b clinical trial. The surgeons can safely remove the small tumors through surgery later.

With these clinical trials, Pharmacyte addresses the unmet medical needs of patients by shrinking the tumors. In the second instance, the clinical trial helps to validate the safety and effectiveness of the Cell-in-Box in humans.

Kenneth said the company is planning to change the way hard to treat diseases that are cured in the future by validating its technology in a clinical trial. It is continually developing new cell lines, mainly genetically engineered cell lines, to cure several diseases. The validation of Cell-in-Box removes the boundaries to treat diseases.

Business

Indiva Ltd (OTCMKTS:NDVAF) Signs A Financing And A White Label Production Agreement With Dycar Pharmaceuticals Ltd: Produces Cannabis Products Under Dycar Brand

Published

on

Indiva Ltd (OTCMKTS:NDVAF) signed a white label manufacturing accord with Dycar Pharmaceutical Ltd. As per the deal, the company will produce high-quality cannabis products under the Dycar brand from its London, Ontario licensed facility. Indiva will also receive financing of up to $4 million from Dycar.

Option to extend the deal

Indiva will repay the debt through its services to Dycar. It has an option to extend the deal for an additional two terms (minimum) at the sole discretion of Dycar. As a result, Indiva will get additional non-dilutive financing of up to $4.5 million.

CEO of Indiva, Niel Marotta, said the company is pleased to rope in a high-quality partner – Dycar into its B2B platform. Both firms share the same vision to deliver high-quality products to satisfy the market needs. He further said the company is excited to work with Dycar and bring innovative products that exceed the consumer and customer expectations.

Funding expected in mid-December 2019

Indiva expects the funding in mid-December 2019 subject to satisfying customary conditions that comprise receiving applicable third-party approvals and executing definitive agreements. The company also expects to receive financing of up to $4 million through unsecured convertible debentures. Each debenture is priced at $1000 and convertible to 5,000 common shares (at $0.20 for each share) of Indiva. The debenture holders will receive an interest of 10% and paid semi-annually (on December 31 and June 30). Issued debentures have a maturity of 36 months from the date of issue.

In Q3 2019, Indiva posted revenues of $185,539. The company received the nod for the distribution of pre-rolls, dry flower, and capsules to the customers in Quebec. It will also offer extraction services as per the accord signed in August 2019 to TerrAscend. Indiva will receive a minimum of 800 kg of dry flower annually from TerrAscend.

Marotta said the company is poised to report significant growth next year. He praised the strengths of his teams and contributions from partners for achieving commercial scale in such a short period. Indiva expects to meet the needs of 90% of the eligible customers by providing high-quality products.

Continue Reading

Business

Health Canada Authorizes Delta 9 Cannabis Inc (OTCMKTS:VRNDF) To Market Edible Cannabis Products, And Cannabis Extracts

Published

on

Health Canada has authorized Delta 9 Cannabis Inc (OTCMKTS:VRNDF) to sell edible cannabis products, cannabis topical, and cannabis extracts. Chief Executive Officer of Delta, John Arbuthnot, said the approval from Health Canada permitting the sale of cannabis products is a milestone for the company.

Sells cannabis extracts on January 5, 2020

Delta has submitted notifications for innovative nine cannabis products to Health Canada on November 5, 2019. The updated processing license received from Health Canada on December 4, 2019, allows Delta to sell cannabis extracts with effective from January 5, 2020. John said the team at Delta worked relentlessly to introduce dried cannabis extracts, disposable vape oil pens, and vaporizable oil cartridges. According to the CEO, the company will begin shipment of cannabis products in early 2020.

Vaporizable cannabis oils

Delta is currently working with Westleaf Inc., with the help of Westleaf Labs LP for the development of disposable vape pens and vaporizable oil cartridges. These innovative products will comprise cannabis terpenes and distilled cannabis oil. Delta will brand these products under the brand names: Blast, Cruise, and Harmony that comprise active cannabinoids in different concentrations. The customers can buy vape products for recreational use in Q1 2020.

Dried sift cannabis products for recreational use

Delta is developing the sapphire line of sift cannabis (dried) products for recreational use. It sifts the blended products and later refines them. The resulting yellow/ brownish fine powder comprises lower levels of low potency plant materials and higher levels of high potency resin glands. It has a potency of over three times that of dried white flower cannabis. The customers can purchase dried sift cannabis products for recreational use in Q1 next year.

Delivers cannabinoids through nanoparticle technology

In Canada, Delta received an exclusive license to produce, and market products developed using Nanosphere Health Sciences Inc’s patented technology. The cannabinoids are delivered through nanoparticle technology of Nanosphere Health. Both companies are engaged in developing the first product to suit the needs of Canadian customers. Delta will produce intranasal products, transdermal viscous gels, and intraoral products using the nanosphere delivery system. It ensures precise dosage, faster results, and high bioavailability.

Delta focused on expanding the Winnipeg facilities in Q3 2019. The expansion helps the company to produce high-quality cannabis products.

Continue Reading

Business

Greenstar Biosciences Corp (OTCMKTS:GTSIF) Strengthens Executive Management Team: Pursues Debt Settlement Agreements For $66,000

Published

on

Greenstar Biosciences Corp (OTCMKTS:GTSIF) has announced the appointment of Mr. Brian Zastiko as a Chief Finance Officer. His appointment at Greenstar is effective from December 6, 2019, and replaces Alexander McAulay. The company signed a deal with Invictus Accounting Group LLP to provide strategic advisory services and CFO.

Brings expertise in financial reporting

Brian held the position of Senior Consultant at Invictus. He brings thirteen years of experience in public sector companies and privately held companies operating in the cannabis space, utility, production, agriculture industries. Brian has expertise in capital markets, corporate governance and financial reporting. He also served as Manager at Ernst & Young. During his stint at Ernst & Young, he obtained CA.

CEO of Greenstar, Rahim Rajwani, said the company is pleased with the appointment of Brian to its executive management team. He will play a vital role in the expansion efforts of Greenstar. The deal with Invictus and the appointment of Brian are the right steps taken by the company because it strengthens the management team for M&A.

Pursues debt settlement agreements

Greenstar has pursued the debt settlement lead by CFO with two creditors for $66,000. As part of the deal, the company will issue 507,692 common shares (at a share price of $0.13).

Secures DTC eligibility

Greenstar has secured the DTC eligibility from the Depository Trust Company (DTC) to facilitate electronic transfer and settlement of common shares in the US. Depository Trust & Clearing Corporation’s subsidiary – DTC is engaged in managing electronic clearing and settlement for the publicly traded companies. The electronic clearing and settlement expedite faster transactions and settlements between the investors and brokers. As a result of DTC eligibility, the customers of Greenstar will benefit from reduced transaction charges. It improves liquidity and offers additional exposure to institutional investors and the US.

Cowlitz produces high-quality cannabis

Greenstar said Cowlitz County Cannabis Cultivation Inc, its tenant partner, has completed four separate grow rooms. It completes the expansion of the first phase and allows Cowlitz to manufacture good quality cannabis. Cowlitz provided LED lights in the four grow rooms to achieve operational efficiency of cultivation and cost reduction in operating costs to improve margins.

Continue Reading

FEATURED STORIES

Business16 hours ago

Indiva Ltd (OTCMKTS:NDVAF) Signs A Financing And A White Label Production Agreement With Dycar Pharmaceuticals Ltd: Produces Cannabis Products Under Dycar Brand

Post Views: 94 Indiva Ltd (OTCMKTS:NDVAF) signed a white label manufacturing accord with Dycar Pharmaceutical Ltd. As per the deal,...

Business16 hours ago

Health Canada Authorizes Delta 9 Cannabis Inc (OTCMKTS:VRNDF) To Market Edible Cannabis Products, And Cannabis Extracts

Post Views: 125 Health Canada has authorized Delta 9 Cannabis Inc (OTCMKTS:VRNDF) to sell edible cannabis products, cannabis topical, and...

Business16 hours ago

Greenstar Biosciences Corp (OTCMKTS:GTSIF) Strengthens Executive Management Team: Pursues Debt Settlement Agreements For $66,000

Post Views: 67 Greenstar Biosciences Corp (OTCMKTS:GTSIF) has announced the appointment of Mr. Brian Zastiko as a Chief Finance Officer....

Business17 hours ago

Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) Reports Sales Of $9.71 Million In Q3 2019

Post Views: 72 Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) has reported sales of $9.71 million in Q3 2019. Its joint venture...

Business17 hours ago

Supreme Cannabis Company Inc (OTCMKTS:SPRWF) Introduces Production, And Packaging Facility In Ontario: Expects To Begin Packaging Of Whole Flowers In Q4 2020

Post Views: 74 Supreme Cannabis Company Inc (OTCMKTS:SPRWF) unveils a dedicated packaging, production, and processing facility based in Kitchener, Ontario....

Medical Marijuana Inc Medical Marijuana Inc
Business17 hours ago

Dr. Stuart Titus Of Medical Marijuana Inc (OTCMKTS:MJNA) Congratulates Anivasa For Approving The Regulation Of Medical Marijuana In Brazil

Post Views: 64 HempMeds Brasil, a subsidiary of Medical Marijuana Inc (OTCMKTS:MJNA), has congratulated ANIVASA and other health officials, who...

Whats Hot